VC biotech funding drops 46% in first quarter as firms guard against bear market

Just when biotechs could use cash the most, the well has dried up. Venture financing deal value for U.S.-based biotechs decreased by 46% in the first quarter, compared to the same period a year ago, GlobalData said.